The U.S. Food and Drug Administration granted Plus Therapeutics’ investigational radiopharmaceutical REYOBIQ (rhenium‑186 obisbemeda) orphan drug designation for the treatment of pediatric malignant gliomas and, as an extension, pediatric ependymoma.
Orphan drug designation confers seven years of market exclusivity upon approval, tax credits for qualified clinical‑trial expenses, and exemption from certain regulatory fees. These incentives reduce development costs and provide a competitive advantage in a niche oncology segment with limited therapeutic options.
Pediatric malignant gliomas and ependymoma are classified as rare diseases, affecting fewer than 200,000 people in the United States. Ependymoma is estimated to affect about 19,340 individuals nationwide, while malignant gliomas are a leading cause of cancer death among children and young adults, though specific pediatric prevalence figures are not publicly available.
The designation comes at a time when the pediatric high‑grade glioma landscape remains sparse. Jazz Pharmaceuticals received accelerated approval in August 2025 for dordaviprone (ONC201) in a subset of pediatric high‑grade glioma, but no other therapies have received regulatory approval for this indication, underscoring the unmet need that REYOBIQ seeks to address.
Plus Therapeutics is advancing REYOBIQ through several clinical programs. The ReSPECT‑PBC trial is evaluating the agent in pediatric high‑grade glioma and ependymoma, with preliminary data expected in Q3 2026. The ReSPECT‑LM Phase 2 trial for leptomeningeal metastases is also underway, with results slated for release in Q3 2026, and the ReSPECT‑GBM Phase 2 trial for recurrent glioblastoma is expected to complete enrollment and report data in Q4 2026. The pediatric brain cancer trial is supported by a $3 million grant from the U.S. Department of Defense’s Peer Reviewed Cancer Research Program.
Marc Hedrick, MD, President and CEO of Plus Therapeutics, said, “Receiving orphan drug designation for REYOBIQ in pediatric malignant gliomas, including the broader scope for progressive pediatric ependymoma, is an important milestone and further validates our approach to delivering targeted radiotherapy directly to CNS tumors.” He added, “We believe REYOBIQ’s ability to deliver high‑dose radiation precisely to tumor sites while minimizing exposure to healthy brain tissue has the potential to meaningfully improve outcomes in this underserved patient population.”
The designation strengthens the commercial viability of REYOBIQ, positioning it as a potential first‑in‑class therapy for a high‑need pediatric population. By securing regulatory incentives and exclusivity, Plus Therapeutics gains a strategic advantage in a niche oncology market, reinforcing its focus on CNS oncology and bolstering investor confidence in the company’s pipeline.
In addition to its therapeutic pipeline, Plus Therapeutics operates CNSide Diagnostics, a diagnostic business that develops cerebrospinal fluid assay platforms for detecting metastatic CNS cancers, further diversifying the company’s portfolio within the central nervous system space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.